The human acidic fibroblast growth factor acts as angiogenic agent.

CardioVascular BioTherapeutics received approval on its patent describing the technology to produce human acidic fibroblast growth factor, its delivery via direct injection into the heart muscle, and the therapeutic utility of this protein in the heart as an agent to stimulate angiogenesis.

“The technology covered by this patent involves the injection of our protein drug candidate directly into the damaged heart muscle of patients suffering from coronary artery disease,” explains Thomas J. Stegmann, M.D., CMO and co-president.

Daniel Montano, CEO and co-president adds that, “the allowance of this patent provides CVBT with tremendous opportunity over the next 12 years to effectively treat severe coronary artery disease. We feel a growing body of evidence indicates that for angiogenesis therapy in the heart to work optimally, the angiogenic agent must be a protein, and that this protein should be injected directly into the heart muscle, two critical points covered in our patent.”

The patent is entitled, “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.”

Previous articleOrganon Extends Research Interest in China
Next articleAVI and Eleos Ink p53 Cross-License Deal